Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee

David A. Rodeberg, Moody D. Wharam, Elizabeth R. Lyden, Julie A. Stoner, Kenneth Brown, Suzanne L. Wolden, Charles N. Paidas, Sarah S. Donaldson, Douglas S. Hawkins, Sheri L. Spunt, Carola A.S. Arndt

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The majority of intermediate-risk rhabdomyosarcoma (RMS) patients have gross residual disease (Group III) after their first operative procedure. It is currently not known if local control rates can be maintained when, following induction chemotherapy, the radiation therapy (RT) dose is decreased after a delayed primary excision (DPE). To answer this question we evaluated patients enrolled on COG D9803 (1999-2005) who had Group III tumors of the bladder dome, extremity or trunk (thorax, abdomen and pelvis) were candidates for DPE at Week 12 if the primary tumor appeared resectable. RT dose was then adjusted by the completeness of DPE: no evidence of disease 36 Gy, microscopic residual 41.4 Gy and gross residual disease (GRD) 50.4 Gy. A total of 161 Group III patients were evaluated (24 bladder dome, 63 extremity and 74 trunk). Seventy-three patients (45%) underwent DPE which achieved removal of all gross disease in 61 (84%) who were then eligible for reduced RT dose (43/73 received 36 Gy, 19/73 received 41.4 Gy). The local 5-year failure rate (0% for bladder dome, 7% for extremity and 20% for trunk) was similar to IRS-IV, which did not encourage DPE and did not allow for DPE adapted RT dose reduction. In conclusion, DPE was performed in 45% of Group III RMS patients with tumors at select anatomic sites (bladder dome, extremity and trunk) and 84% of those who had DPE were eligible for RT dose reduction. Local control outcomes were similar to historic results with RT alone.

Original languageEnglish (US)
Pages (from-to)204-211
Number of pages8
JournalInternational Journal of Cancer
Volume137
Issue number1
DOIs
StatePublished - Jul 1 2015

Fingerprint

Rhabdomyosarcoma
Sarcoma
Radiotherapy
Extremities
Urinary Bladder
Induction Chemotherapy
Operative Surgical Procedures
Pelvis
Urinary Bladder Neoplasms
Abdomen
Neoplasms
Thorax

Keywords

  • bladder
  • extremity
  • pediatric
  • second look operation
  • trunk

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma : A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. / Rodeberg, David A.; Wharam, Moody D.; Lyden, Elizabeth R.; Stoner, Julie A.; Brown, Kenneth; Wolden, Suzanne L.; Paidas, Charles N.; Donaldson, Sarah S.; Hawkins, Douglas S.; Spunt, Sheri L.; Arndt, Carola A.S.

In: International Journal of Cancer, Vol. 137, No. 1, 01.07.2015, p. 204-211.

Research output: Contribution to journalArticle

Rodeberg, David A. ; Wharam, Moody D. ; Lyden, Elizabeth R. ; Stoner, Julie A. ; Brown, Kenneth ; Wolden, Suzanne L. ; Paidas, Charles N. ; Donaldson, Sarah S. ; Hawkins, Douglas S. ; Spunt, Sheri L. ; Arndt, Carola A.S. / Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma : A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. In: International Journal of Cancer. 2015 ; Vol. 137, No. 1. pp. 204-211.
@article{290e7216c8b6465281d7b40d2bf5fdab,
title = "Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee",
abstract = "The majority of intermediate-risk rhabdomyosarcoma (RMS) patients have gross residual disease (Group III) after their first operative procedure. It is currently not known if local control rates can be maintained when, following induction chemotherapy, the radiation therapy (RT) dose is decreased after a delayed primary excision (DPE). To answer this question we evaluated patients enrolled on COG D9803 (1999-2005) who had Group III tumors of the bladder dome, extremity or trunk (thorax, abdomen and pelvis) were candidates for DPE at Week 12 if the primary tumor appeared resectable. RT dose was then adjusted by the completeness of DPE: no evidence of disease 36 Gy, microscopic residual 41.4 Gy and gross residual disease (GRD) 50.4 Gy. A total of 161 Group III patients were evaluated (24 bladder dome, 63 extremity and 74 trunk). Seventy-three patients (45{\%}) underwent DPE which achieved removal of all gross disease in 61 (84{\%}) who were then eligible for reduced RT dose (43/73 received 36 Gy, 19/73 received 41.4 Gy). The local 5-year failure rate (0{\%} for bladder dome, 7{\%} for extremity and 20{\%} for trunk) was similar to IRS-IV, which did not encourage DPE and did not allow for DPE adapted RT dose reduction. In conclusion, DPE was performed in 45{\%} of Group III RMS patients with tumors at select anatomic sites (bladder dome, extremity and trunk) and 84{\%} of those who had DPE were eligible for RT dose reduction. Local control outcomes were similar to historic results with RT alone.",
keywords = "bladder, extremity, pediatric, second look operation, trunk",
author = "Rodeberg, {David A.} and Wharam, {Moody D.} and Lyden, {Elizabeth R.} and Stoner, {Julie A.} and Kenneth Brown and Wolden, {Suzanne L.} and Paidas, {Charles N.} and Donaldson, {Sarah S.} and Hawkins, {Douglas S.} and Spunt, {Sheri L.} and Arndt, {Carola A.S.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1002/ijc.29351",
language = "English (US)",
volume = "137",
pages = "204--211",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma

T2 - A report from the Children's Oncology Group Soft Tissue Sarcoma Committee

AU - Rodeberg, David A.

AU - Wharam, Moody D.

AU - Lyden, Elizabeth R.

AU - Stoner, Julie A.

AU - Brown, Kenneth

AU - Wolden, Suzanne L.

AU - Paidas, Charles N.

AU - Donaldson, Sarah S.

AU - Hawkins, Douglas S.

AU - Spunt, Sheri L.

AU - Arndt, Carola A.S.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - The majority of intermediate-risk rhabdomyosarcoma (RMS) patients have gross residual disease (Group III) after their first operative procedure. It is currently not known if local control rates can be maintained when, following induction chemotherapy, the radiation therapy (RT) dose is decreased after a delayed primary excision (DPE). To answer this question we evaluated patients enrolled on COG D9803 (1999-2005) who had Group III tumors of the bladder dome, extremity or trunk (thorax, abdomen and pelvis) were candidates for DPE at Week 12 if the primary tumor appeared resectable. RT dose was then adjusted by the completeness of DPE: no evidence of disease 36 Gy, microscopic residual 41.4 Gy and gross residual disease (GRD) 50.4 Gy. A total of 161 Group III patients were evaluated (24 bladder dome, 63 extremity and 74 trunk). Seventy-three patients (45%) underwent DPE which achieved removal of all gross disease in 61 (84%) who were then eligible for reduced RT dose (43/73 received 36 Gy, 19/73 received 41.4 Gy). The local 5-year failure rate (0% for bladder dome, 7% for extremity and 20% for trunk) was similar to IRS-IV, which did not encourage DPE and did not allow for DPE adapted RT dose reduction. In conclusion, DPE was performed in 45% of Group III RMS patients with tumors at select anatomic sites (bladder dome, extremity and trunk) and 84% of those who had DPE were eligible for RT dose reduction. Local control outcomes were similar to historic results with RT alone.

AB - The majority of intermediate-risk rhabdomyosarcoma (RMS) patients have gross residual disease (Group III) after their first operative procedure. It is currently not known if local control rates can be maintained when, following induction chemotherapy, the radiation therapy (RT) dose is decreased after a delayed primary excision (DPE). To answer this question we evaluated patients enrolled on COG D9803 (1999-2005) who had Group III tumors of the bladder dome, extremity or trunk (thorax, abdomen and pelvis) were candidates for DPE at Week 12 if the primary tumor appeared resectable. RT dose was then adjusted by the completeness of DPE: no evidence of disease 36 Gy, microscopic residual 41.4 Gy and gross residual disease (GRD) 50.4 Gy. A total of 161 Group III patients were evaluated (24 bladder dome, 63 extremity and 74 trunk). Seventy-three patients (45%) underwent DPE which achieved removal of all gross disease in 61 (84%) who were then eligible for reduced RT dose (43/73 received 36 Gy, 19/73 received 41.4 Gy). The local 5-year failure rate (0% for bladder dome, 7% for extremity and 20% for trunk) was similar to IRS-IV, which did not encourage DPE and did not allow for DPE adapted RT dose reduction. In conclusion, DPE was performed in 45% of Group III RMS patients with tumors at select anatomic sites (bladder dome, extremity and trunk) and 84% of those who had DPE were eligible for RT dose reduction. Local control outcomes were similar to historic results with RT alone.

KW - bladder

KW - extremity

KW - pediatric

KW - second look operation

KW - trunk

UR - http://www.scopus.com/inward/record.url?scp=84930417796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930417796&partnerID=8YFLogxK

U2 - 10.1002/ijc.29351

DO - 10.1002/ijc.29351

M3 - Article

C2 - 25418440

AN - SCOPUS:84930417796

VL - 137

SP - 204

EP - 211

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -